Quantcast
Last updated on April 16, 2014 at 11:49 EDT

Latest Cytochroma Stories

2013-01-08 20:21:23

Acquisition Includes Replidea(TM) and Alpharen(TM), Both in Phase 3 Clinical Trials with Kidney Disease Patients MARKHAM, ON, Jan. 8, 2013 /PRNewswire/ - Cytochroma today announced that it has entered into a definitive agreement with OPKO Health, Inc. (NYSE:OPK) under which Cytochroma, a privately held pharmaceutical company with operations in Markham, ON and Bannockburn, IL, will be acquired by OPKO. Through this transaction, OPKO will acquire worldwide rights to Cytochroma's two...

2012-09-20 02:29:59

MARKHAM, ON, Sept. 20, 2012 /PRNewswire/ - Cytochroma today announced the initiation of a phase 3 study of CTAP101 capsules ("CTAP101 Capsules") in patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. The newly initiated trial is the first of two identical randomized, double-blind, placebo controlled, multi-site studies intended to establish the safety and efficacy of CTAP101 Capsules as a new treatment for SHPT in...

2012-06-01 02:24:41

MARKHAM, ON, June 1, 2012 /PRNewswire/ - Cytochroma today announced that it has regained the rights to all indications in the United States (US) and in Asian territories to lunacalcipol (previously known as CTA018) through the termination of a license agreement between Cytochroma and Mitsubishi Tanabe Pharma Corporation ("MTPC").  MTPC and Cytochroma mutually decided to suspend further development of lunacalcipol injection based on changing US market dynamics. "We are...

2012-05-11 02:23:45

MARKHAM, ON, May 11, 2012 /PRNewswire/ - Cytochroma today announced positive clinical trial results for its lead product, CTAP101 Capsules.  In a recently completed Phase 2b trial, CTAP101 Capsules effectively and safely lowered elevated plasma intact parathyroid hormone (iPTH) in patients with Stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.  These findings, as well as two other presentations on CTAP101 Capsules, are being featured at the National...

2012-04-03 02:27:11

MARKHAM, ON, April 3, 2012 /PRNewswire/ - Cytochroma today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for US Patent Application # 13/244,945.  This patent application, entitled "Method for Treating Secondary Hyperparathyroidism in CKD", covers the anticipated method of use of the Company's lead product, CTAP101 Capsules, which is in phase 3 development for treating patients with Stage 3 or 4 chronic kidney disease (CKD),...

2012-02-29 07:00:00

MARKHAM, ON, Feb. 29, 2012 /PRNewswire/ - Cytochroma today announced that Dr. Charles W. Bishop, Cytochroma's President and Chief Executive Officer, will present a corporate overview at the Cowen and Company 32(nd) Annual Health Care Conference.  This presentation is scheduled at 2:00 PM ET on Monday, March 5, 2012 at the Boston Marriott Copley Place. About Cytochroma Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and...

2011-09-07 07:00:00

MARKHAM, ON, Sept. 7, 2011 /PRNewswire/ - Cytochroma today announced that the Company will be presenting a corporate overview at the following investor conferences: -- Charles W. Bishop, Cytochroma's President and Chief Executive Officer will be presenting at the Stifel Nicolaus Healthcare Conference 2011 at 4:25 PM ET on Wednesday, September 7, 2011 at the Four Seasons Hotel in Boston. -- Eric J. Messner, Cytochroma's Chief...

2011-07-26 11:00:00

MARKHAM, ON, July 26, 2011 /PRNewswire/ - Cytochroma today announced that it has closed an equity investment of $1 million from the Investment Accelerator Fund, a fund of the Province of Ontario that invests in emerging Ontario technology companies.  The investment is designed to advance and accelerate the Company's development of CTAP101 Capsules, a product currently in a Phase 2b study for the treatment of secondary hyperparathyroidism associated with vitamin D insufficiency in...

2011-06-13 07:00:00

MARKHAM, ON, June 13, 2011 /PRNewswire/ - Cytochroma today announced the appointment of Dr. Cynthia Lavoie and Mr. Osamu Otani to its Board of Directors. Dr. Lavoie replaced Dr. Luc Marengre as VG Partners' representative, and Mr. Otani replaced Dr. Seiichi Kiso as Mitsubishi Tanabe Pharma Corporation's representative on the Company's Board. The number of Board members remains unchanged at six members. "We are pleased to have Cynthia and Osamu join the Cytochroma Board. They bring...

2011-02-17 07:00:00

MARKHAM, ON, Feb. 17 /PRNewswire/ - Cytochroma today announced the initiation of a repeat-dose safety and efficacy study of CTAP101 Capsules in patients with vitamin D insufficiency, secondary hyperparathyroidism (SHPT) and stage 3 chronic kidney disease (CKD). "Vitamin D insufficiency in CKD patients is a significant problem associated with increased mortality and morbidity and for which no approved treatment is available," stated Joel Z. Melnick, M.D., Cytochroma's Vice President,...